NWPHF (Newron Pharmaceuticals SpA) Total Current Liabilities: $58.70 Mil (As of Dec. 2025)


NWPHF Newron Pharmaceuticals SpA NWPHF
64 GF Score
Price $20.00
GF Value $21.26
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Total Current Liabilities?

Newron Pharmaceuticals SpA NWPHF 64 Total Current Liabilities is $58.70 Mil as of Dec. 2025. GuruFocus rates NWPHF with a GF Score™ of 64/100 and a GF Value™ of $21.26. The stock has 5 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Newron Pharmaceuticals SpA's total current liabilities for the quarter that ended in Dec. 2025 was $58.70

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Newron Pharmaceuticals SpA Total Current Liabilities Related Terms

Newron Pharmaceuticals SpA Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Total Current Liabilities Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.13 5.34 31.54 24.61 58.70

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.54 5.79 24.61 46.23 58.70
NWPHF
64GF Score
Newron Pharmaceuticals SpA NWPHF
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Newron Pharmaceuticals SpA's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.388+44.005
+Other Current Liabilities+Current Deferred Liabilities
=10.308+0
=58.70

Newron Pharmaceuticals SpA's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.388+44.005
+Other Current Liabilities+Current Deferred Liabilities
=10.308+0
=58.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $58.70 Mil mean?
Newron Pharmaceuticals SpA (NWPHF) has a Total Current Liabilities of $58.70 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Total Current Liabilities too high?
Newron Pharmaceuticals SpA's current Total Current Liabilities is $58.70 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Total Current Liabilities compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Total Current Liabilities of $58.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Total Current Liabilities is $58.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Newron Pharmaceuticals SpA (NWPHF) has a current Total Current Liabilities of $58.70 Mil. The stock's GF Value™ is $21.26, compared to a current price of $20.00 — trading 5.9% below its estimated fair value. The current Total Current Liabilities is $58.70 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (NWPHF), the current Total Current Liabilities is $58.70 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (NWPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of $20.00 is trading 5.9% below its estimated GF Value™ of $21.26.

Key valuation signals for NWPHF:

  • Total Current Liabilities: $58.70 Mil
  • GF Value™: $21.26 vs. price of $20.00 (5.9% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the NWPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for NWPHF

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.00
Price
$21.26
GF Value